Non-Hodgkin lymphoma in Chile: a review of 207 consecutive adult cases by a panel of five expert hematopathologists.

abstract：:Our aim was to describe a large population-based cohort of diffuse large B-cell lymphoma (DLBCL) during the last decade, evaluating possible improvement in survival and to identify subgroups in need of novel treatment strategies. The study population encompassed all patients diagnosed with DLBCL in Sweden from 2000 th...

journal_title：Leukemia & lymphoma

authors： Székely E,Hagberg O,Arnljots K,Jerkeman M

更新日期：2014-08-01 00:00:00

abstract：:Chronic myeloid leukemia therapy has remarkably improved with the use of frontline BCR-ABL kinase inhibitors such that newly diagnosed patients have minimal disease manifestations or progression. Effective control of disease may also set the stage for eventual 'cure' of this leukemia. However, the existence of Philade...

journal_title：Leukemia & lymphoma

authors： Donato NJ,Peterson LF

更新日期：2011-02-01 00:00:00

abstract：:To understand the relationship between bcl-2 protein expression and the cell cycle during the processes of differentiation, we examined bcl-2 protein levels expressed during cell cycle phases in differentiating HL-60 human leukemia cells by using a two-color flow cytometric method. In exponentially proliferating HL-60...

journal_title：Leukemia & lymphoma

authors： Kumakura S,Ishikura H,Tsumura H,Nakashima A,Sato Y,Kobayashi S

更新日期：2000-01-01 00:00:00

abstract：:Over a period of 14 years, 50 patients (12 children and 38 adults) of whom 46 had acute myeloid leukemia (AML) and 4 had myelodysplastic syndrome characterized by the t(8;21)(q22;q22) translocation were referred to the Royal Marsden Hospital. The clinicopathological features of these cases were analyzed to determine t...

journal_title：Leukemia & lymphoma

authors： Rege K,Swansbury GJ,Atra AA,Horton C,Min T,Dainton MG,Matutes E,Durosinmi M,Treleaven JG,Powles RL,Catovsky D

更新日期：2000-12-01 00:00:00

abstract：:CD95 is a cell-surface receptor that mediates apoptosis. A possible association between CD95 mutations and extranodal diffuse large B-cell lymphomas (DLBCL) has been reported. To further elucidate this question, a mutation analysis within the 5' region and exon 9 of CD95 was performed in a series of 66 DLBCL patients,...

journal_title：Leukemia & lymphoma

authors： Scholl V,Stefanoff CG,Hassan R,Spector N,Renault IZ

更新日期：2007-05-01 00:00:00

abstract：:A two-year-old boy presented with pancytopenia. Bone marrow examination revealed an aplastic marrow with prominent immature plasma cell proliferation, which mimicked plasma cell leukemia. Immunohistochemistry, however, revealed a polyclonal population consistent with a reactive process, excluding plasma cell neoplasia...

journal_title：Leukemia & lymphoma

authors： Kikuchi M,Ohsaka A,Chiba Y,Sato M,Muraosa Y,Hoshino H

更新日期：1999-09-01 00:00:00

abstract：:Factors associated with failure of antifungal therapy were examined in 42 cancer patients with fusariosis (1987-1997). Thirty-six patients (86%) had leukemia and 39 (93%) were neutropenic. Disseminated infection was the most common presentation. The majority (83%) received amphotericin B-based therapy. Thirty patients...

journal_title：Leukemia & lymphoma

authors： Kontoyiannis DP,Bodey GP,Hanna H,Hachem R,Boktour M,Girgaway E,Mardani M,Raad II

更新日期：2004-01-01 00:00:00

abstract：:The short segments of cDNA encoding glycoprotein (GP)Ib alpha, GPIIb, GPIIIa and platelet factor (PF) 4 were amplified using reverse transcriptase-polymerase chain reaction (RT-PCR) in order to characterize various types of megakaryoblasts. Cell lines with megakaryocytic features (K562, CMK and HEL) were tested. GPIb ...

journal_title：Leukemia & lymphoma

authors： Yasunaga M,Ryo R,Sugano W,Yamaguchi N

更新日期：1992-08-01 00:00:00

abstract：:Vasculitis may accompany neoplasias and be of paraneoplastic type or associated with drugs used in patient treatment. We evaluated skin biopsies of twenty-eight cases with vasculitis accompanying leukemias reviewed and clinical outcome was evaluated. Eleven of the 28 cases had paraneoplastic vasculitis and 17 had vasc...

journal_title：Leukemia & lymphoma

authors： Paydaş S,Zorludemir S,Sahin B

更新日期：2000-12-01 00:00:00

abstract：:The objective was to evaluate the feasibility and efficacy of a short-term, multi-agent and dose intensive regimen in AIDS patients with Burkitt or Burkitt-like lymphoma (BL/BLL) and to compare its efficacy with that of a conventional regimen. This was a retrospective, multi-center cohort study of all HIV-1-infected p...

journal_title：Leukemia & lymphoma

authors： Hoffmann C,Wolf E,Wyen C,Fätkenheuer G,Van Lunzen J,Stellbrink HJ,Stoehr A,Plettenberg A,Jaeger H,Noppeney R,Hentrich M,Goekbuget N,Hoelzer D,Horst HA

更新日期：2006-09-01 00:00:00

abstract：:A leukemia-associated CD9 glycoprotein antigen released into the extracellular milieu from acute lymphoblastic leukemia cells has been detected using a unique lectin-monoclonal antibody immunoassay. It has been demonstrated that the release of CD9 antigen is an active process and is associated with active cell growth....

journal_title：Leukemia & lymphoma

authors： Komada Y,Sakurai M

更新日期：1994-02-01 00:00:00

abstract：:The percentage of blasts in the bone marrow aspirates at day 7 or 14 of induction therapy in pediatric ALL patients is an indicator of rapid early response and an independent prognostic factor for long term outcome. Discrepancies between the percentages of blasts in bone marrow aspirates compared to biopsies have been...

journal_title：Leukemia & lymphoma

authors： Countouriotis A,Landaw EM,Naeim F,Moore TB,Sakamoto KM

更新日期：2004-04-01 00:00:00

abstract：:Nilotinib has shown favorable safety in patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic (CML-CP) or accelerated phase (CML-AP) who failed prior imatinib, and superior efficacy over imatinib in newly diagnosed Ph+ patients with CML-CP. Reported here are the efficacy and sa...

journal_title：Leukemia & lymphoma

authors： Nicolini FE,Masszi T,Shen Z,Gallagher NJ,Jootar S,Powell BL,Dorlhiac-Llacer PE,Zheng M,Szczudlo T,Turkina A

更新日期：2012-05-01 00:00:00

abstract：:Patients with chronic lymphocytic lymphoma (CLL) with high-risk cytogenetics [del(11q)(q22.3) or del(17p)(p13.1)] have limited therapeutic options and their prognosis remains poor. This analysis was conducted to determine the clinical activity of lenalidomide in patients with high-risk disease. Relapsed/refractory pat...

journal_title：Leukemia & lymphoma

authors： Sher T,Miller KC,Lawrence D,Whitworth A,Hernandez-Ilizaliturri F,Czuczman MS,Miller A,Lawrence W,Bilgrami SA,Sood R,Wood MT,Block AW,Lee K,Chanan-Khan AA

更新日期：2010-01-01 00:00:00

abstract：:Infection, relapse, and GVHD can complicate allogeneic hematopoietic stem cell transplantation (allo-HSCT). Although the effect of poor immune recovery on infection risk is well-established, there are limited data on the effect of immune reconstitution on relapse and survival, especially following T-cell depletion (TC...

journal_title：Leukemia & lymphoma

authors： Goldberg JD,Zheng J,Ratan R,Small TN,Lai KC,Boulad F,Castro-Malaspina H,Giralt SA,Jakubowski AA,Kernan NA,O'Reilly RJ,Papadopoulos EB,Young JW,van den Brink MR,Heller G,Perales MA

更新日期：2017-08-01 00:00:00

abstract：:The present study has explored the possible value of sCA-125 as a prognostic factor in Hodgkin's lymphoma (HL). From August 1992 to June 2005 sCA-125 was measured at presentation and at the end of the treatments in 221 newly diagnosed adult patients with HL. In this study 90/221 (41%) patients showed a value greater t...

journal_title：Leukemia & lymphoma

authors： Russo F,Lastoria S,Svanera G,Capobianco G,de Chiara A,Francia Rd,Squame E,de Martinis F,Pinto A

更新日期：2007-04-01 00:00:00

abstract：:The t(5;17) variant of acute promeylocytic leukemia (APL) expresses a fusion of nucleophosmin (NPM) with the retinoic acid receptor alpha (RARA). We have previously shown that NPM-RAR is a binding partner of the tumor necrosis factor (TNF) receptor type-I-associated DEATH domain protein, TRADD. Binding of TNF to its r...

journal_title：Leukemia & lymphoma

authors： Chattopadhyay A,Abecassis I,Redner RL

更新日期：2015-01-01 00:00:00

abstract：:The tyrosine kinase inhibitors (TKIs), nilotinib, ponatinib, and dasatinib (but not bosutinib or imatinib), are associated with vascular adverse events (VAEs) in chronic myeloid leukemia (CML). Though the mechanism is inadequately understood, an effect on vascular cells has been suggested. We investigated the effect o...

journal_title：Leukemia & lymphoma

authors： Gover-Proaktor A,Granot G,Pasmanik-Chor M,Pasvolsky O,Shapira S,Raz O,Raanani P,Leader A

更新日期：2019-01-01 00:00:00

abstract：:CT and MRI are the most efficient imaging techniques for diagnosing lymphomas while Gallium-67 scintigraphy is used to assess treatment results. In this review, the imaging aspects of lymphoma are addressed according to anatomical subregions, from the orbit to the trachea, Waldeyer's ring being the most common site, i...

journal_title：Leukemia & lymphoma

authors： Chisin R,Weber AL

更新日期：1994-01-01 00:00:00

abstract：:Immune suppression is a hallmark of multiple myeloma (MM), but data on soluble factors involved in the fate of immune effector cells are limited. The CXCR3-binding chemokine monokine induced by interferon-gamma (MIG/CXCL9) has been associated with tumor progression, immune escape, and angiogenesis in several malignanc...

journal_title：Leukemia & lymphoma

authors： Bolomsky A,Schreder M,Hübl W,Zojer N,Hilbe W,Ludwig H

更新日期：2016-11-01 00:00:00

abstract：:Although treatment of Hodgkin's disease has been extensively studied in the past, fewer clinical studies are being reported, despite the fact that the optimal therapy for each stage has not yet been established. The pathologic subtypes have not been officially changed for years, although lymphocyte-predominant disease...

journal_title：Leukemia & lymphoma

authors： Hagemeister FB

更新日期：1996-03-01 00:00:00

abstract：:Classical Hodgkin's disease (HD) is a peculiar form of lymphoma characterized by a low frequency of tumor cells, the so-called Hodgkin (H) and Reed/Sternberg (RS) cells, embedded in a background of non-neoplastic (reactive) cells believed to be recruited and activated by H-RS cell-derived cytokines/chemokines. How the...

journal_title：Leukemia & lymphoma

authors： Aldinucci D,Olivo K,Lorenzon D,Poletto D,Gloghini A,Carbone A,Pinto A

更新日期：2005-03-01 00:00:00

abstract：:Despite maturation arrest, blast cells in acute myeloid leukemia (AML) are often capable of expressing lineage-restricted (granulomonocytic or myelomastocytic) differentiation antigens. Tryptases are lineage-associated serine proteases primarily expressed in mast cells, and less abundantly in blood basophils. We have ...

journal_title：Leukemia & lymphoma

authors： Sperr WR,Hauswirth AW,Valent P

更新日期：2002-12-01 00:00:00

abstract：:This single institution cohort study of 132 AML patients investigated the clinical implications of co-mutations detected with a 42-gene NGS panel. In the intermediate-risk cytogenetic group, FLT3-ITD is an adverse prognostic indicator only in the presence of a DNMT3A co-mutation, regardless of NPM1 mutation status. In...

journal_title：Leukemia & lymphoma

authors： Ma J,Dunlap J,Paliga A,Traer E,Press R,Shen L,Fan G

更新日期：2018-08-01 00:00:00

abstract：:CXCR4 directs chronic lymphocytic leukemia (CLL) trafficking within protective tissue niches, and targeting CXCR4 with plerixafor may enhance drug sensitivity. We performed a phase 1 dose escalation study of plerixafor (NCT00694590) with rituximab in 24 patients with relapsed/refractory CLL. Patients received rituxima...

journal_title：Leukemia & lymphoma

authors： Andritsos LA,Byrd JC,Cheverton P,Wu J,Sivina M,Kipps TJ,Burger JA

更新日期：2019-12-01 00:00:00

abstract：:Population level survival of patients with myelodysplastic syndromes (MDS) treated with hypomethylating agents (HMA) is inferior to clinical trials. Using SEER-Medicare data, we identified 2086 MDS patients diagnosed in 2004-13, aged ≥66 years at diagnosis, and receiving ≥1 HMA cycle after 2005. We used multivariate l...

journal_title：Leukemia & lymphoma

authors： Zeidan AM,Hu X,Zhu W,Stahl M,Wang R,Huntington SF,Giri S,Bewersdorf JP,Podoltsev NA,Gore SD,Ma X,Davidoff AJ

更新日期：2020-02-01 00:00:00

abstract：:Plasma cell tumors show an increased incidence in HIV-positive patients. The cases reported in the literature suggest that plasma cell tumors occur in a younger age group than that encountered in the general population. Pathologically, many of these tumors show a plasmablastic morphology. Plasma cell tumors in HIV-pos...

journal_title：Leukemia & lymphoma

authors： Salarieh A,Rao C,Gottesman SR,Alagha O,Todor R,Axiotis CA

更新日期：2005-07-01 00:00:00

abstract：:Information on the use of hypomethylating agents (HMAs) as a pre-transplant cytoreductive therapy in MDS is limited. We retrospectively evaluated outcomes of 172 adult MDS patients, who underwent allogeneic hematopoietic stem cell transplantation between January 2000 and December 2016. Patients were divided into three...

journal_title：Leukemia & lymphoma

authors： Modi D,Kim S,Singh V,Ayash L,Alavi A,Ratanatharathorn V,Uberti JP,Deol A

更新日期：2019-11-01 00:00:00

abstract：:Detection of relapse in acute lymphoblastic leukemia (ALL) is essential for proper management. However, immunophenotypic detection of relapse by flow cytometry in B-lineage ALL can be confounded by several factors, including lack of a unique immunophenotype and modulation of aberrant phenotypes after treatment. We hyp...

journal_title：Leukemia & lymphoma

authors： Kenney B,Zieske A,Rinder H,Smith B

更新日期：2008-01-01 00:00:00

abstract：:The clinical significance and mechanisms of TET2 are not well defined in myeloid malignancies. We detected TET2 mutations and assayed its catalyzing conversion product 5-hydroxymethylcytosine (5-hmC) in 61 Chinese patients with MDS. Ten patients were identified to have TET2 mutations (16.4%). 5-hmC levels in patients ...

journal_title：Leukemia & lymphoma

authors： Liu X,Zhang G,Yi Y,Xiao L,Pei M,Liu S,Luo Y,Zhong H,Xu Y,Zheng W,Shen J

更新日期：2013-11-01 00:00:00